Taming our enemies to make them our allies: Cancer "virotherapy";Apprivoiser nos ennemis pour en faire des alliés: La « virothérapie » anticancéreuse

Medecine/Sciences

Volumn 28, Issue 4, 2012, Pages 339-340

  Lemay, Guy ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL; ANTIBODY SPECIFICITY; DISEASE MODEL; EDITORIAL; HOST RANGE; HUMAN; MEDICAL RESEARCH; METHODOLOGY; MOLECULARLY TARGETED THERAPY; NEOPLASM; ONCOLYTIC VIROTHERAPY; PATHOLOGY; PHYSIOLOGY; UTILIZATION REVIEW; VIRAL PHENOMENA AND FUNCTIONS; VIRUS INFECTION;

ANIMALS; BIOMEDICAL RESEARCH; DISEASE MODELS, ANIMAL; HOST SPECIFICITY; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ORGAN SPECIFICITY; VIRUS DISEASES; VIRUS PHYSIOLOGICAL PROCESSES;

EID: 84860868454     PISSN: 07670974     EISSN: 19585381     Source Type: Journal    
DOI: 10.1051/medsci/2012284001     Document Type: Editorial

References (15)

1. Sinkovics JG, Horvath JC. Natural and genetically engineered viral agents for oncolysis and gene therapy of human cancers. Arch Immunol Ther Exp 2008;56(suppl 1):S3-59.
2. Garber K. China approves world's first oncolytic virus therapy for cancer treatment. J Natl Cancer Inst 2006;98:298-300.
3. Stanford MM, Bell JC, Vähä-Koskela M J V. Novel oncolytic viruses: riding high on the next wave? Cytokine Growth Factor Rev 2010;21:177-83.
4. Koppers-Lalic D, Hoeben RC. Non-human viruses developed as therapeutic agent for use in humans. Rev Med Virol 2011;21:227-39.
5. Cattaneo R, Miest T, Shashkova EV, Barry MA. Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat Rev Microbiol 2008;6:529-40. (Pubitemid 351850977)
6. Russell SJ, Peng K. Measles virus for cancer therapy. Curr Top Microbiol Immunol 2009;330:213-411.
7. Touchefeu Y, Schick U, Harrington KJ. Le virus de la rougeole: un futur traitement en cancérologie? Med Sci (Paris) 2012;28:388-94.
8. Verheije MH, Rottier P J M. Retargeting of viruses to generate oncolytic agents. Adv Virol 2012;2012:1-15.
9. Liu C, Hasegawa K, Russell SJ, et al. Prostate-specific membrane antigen retargeted measles virotherapy for the treatment of prostate cancer. Prostate 2009;69:1128-41.
10. Noyce RS, Bondre DG, Ha MN, et al. Tumor cell marker PVRL4 (Nectin 4) is an epithelial cell receptor for measles virus. PloS Pathog 2011;7:e1002240.
11. Mühlebach MD, Mateo M, Sinn PL, et al. Adherens junction protein nectin-4 is the epithelial receptor for measles virus. Nature 2011;480:530-3.
12. Mateo M, Lopez M. Nectine-4, une protéine clé pour la transmission du virus de la rougeole. Med Sci (Paris) 2012;28:363-5.
13. Leonard V H J, Hodge G, Reyes-del Valle J, et al. Measles virus selectively blind to signaling lymphocytic activation molecule (SLAM; CD150) is attenuated and induces strong adaptive immune responses in rhesus monkeys. J Virol 2010;84:3413-20.
14. Bell JC, Kirn D. MicroRNAs fine-tune oncolytic viruses. Nat Biotechnol 2008;26:1346-8.
15. Leber MF, Bossow S, Leonard VH, et al. MicroRNA-sensitive oncolytic measles viruses for cancer-specific vector tropism. Mol Ther 2009;19:1097-106.